Cargando…
Pharmacological cancer treatment and venous thromboembolism risk
Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189737/ https://www.ncbi.nlm.nih.gov/pubmed/32368194 http://dx.doi.org/10.1093/eurheartj/suaa004 |
_version_ | 1783527560961851392 |
---|---|
author | Muñoz Martín, Andrés J Ramírez, Sara Pérez Morán, Laura Ortega Zamorano, Magdalena Ruiz Benéitez, María Carmen Viñuela Salcedo, Inmaculada Aparicio Escobar, Ignacio García Fernández, José Manuel Soria |
author_facet | Muñoz Martín, Andrés J Ramírez, Sara Pérez Morán, Laura Ortega Zamorano, Magdalena Ruiz Benéitez, María Carmen Viñuela Salcedo, Inmaculada Aparicio Escobar, Ignacio García Fernández, José Manuel Soria |
author_sort | Muñoz Martín, Andrés J |
collection | PubMed |
description | Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE). However, it should be noted, that the risk of VTE is not consistent among all cytotoxic agents. In addition, different supportive care drugs, such as erythropoiesis stimulating agents or granulocyte colony stimulating factors, and hormonotherapy have been associated to an increased risk of VTE. Immunotherapy and molecular-targeted therapies have significantly changed the treatment of cancer over the past decade. The main subtypes include tyrosine-kinase inhibitors, monoclonal antibodies, small molecules, and immunomodulatory agents. The relationship between VTE and targeted therapies remains largely unknown. |
format | Online Article Text |
id | pubmed-7189737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-71897372020-05-04 Pharmacological cancer treatment and venous thromboembolism risk Muñoz Martín, Andrés J Ramírez, Sara Pérez Morán, Laura Ortega Zamorano, Magdalena Ruiz Benéitez, María Carmen Viñuela Salcedo, Inmaculada Aparicio Escobar, Ignacio García Fernández, José Manuel Soria Eur Heart J Suppl Articles Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE). However, it should be noted, that the risk of VTE is not consistent among all cytotoxic agents. In addition, different supportive care drugs, such as erythropoiesis stimulating agents or granulocyte colony stimulating factors, and hormonotherapy have been associated to an increased risk of VTE. Immunotherapy and molecular-targeted therapies have significantly changed the treatment of cancer over the past decade. The main subtypes include tyrosine-kinase inhibitors, monoclonal antibodies, small molecules, and immunomodulatory agents. The relationship between VTE and targeted therapies remains largely unknown. Oxford University Press 2020-04 2020-04-29 /pmc/articles/PMC7189737/ /pubmed/32368194 http://dx.doi.org/10.1093/eurheartj/suaa004 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2020. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Muñoz Martín, Andrés J Ramírez, Sara Pérez Morán, Laura Ortega Zamorano, Magdalena Ruiz Benéitez, María Carmen Viñuela Salcedo, Inmaculada Aparicio Escobar, Ignacio García Fernández, José Manuel Soria Pharmacological cancer treatment and venous thromboembolism risk |
title | Pharmacological cancer treatment and venous thromboembolism risk |
title_full | Pharmacological cancer treatment and venous thromboembolism risk |
title_fullStr | Pharmacological cancer treatment and venous thromboembolism risk |
title_full_unstemmed | Pharmacological cancer treatment and venous thromboembolism risk |
title_short | Pharmacological cancer treatment and venous thromboembolism risk |
title_sort | pharmacological cancer treatment and venous thromboembolism risk |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189737/ https://www.ncbi.nlm.nih.gov/pubmed/32368194 http://dx.doi.org/10.1093/eurheartj/suaa004 |
work_keys_str_mv | AT munozmartinandresj pharmacologicalcancertreatmentandvenousthromboembolismrisk AT ramirezsaraperez pharmacologicalcancertreatmentandvenousthromboembolismrisk AT moranlauraortega pharmacologicalcancertreatmentandvenousthromboembolismrisk AT zamoranomagdalenaruiz pharmacologicalcancertreatmentandvenousthromboembolismrisk AT beneitezmariacarmenvinuela pharmacologicalcancertreatmentandvenousthromboembolismrisk AT salcedoinmaculadaaparicio pharmacologicalcancertreatmentandvenousthromboembolismrisk AT escobarignaciogarcia pharmacologicalcancertreatmentandvenousthromboembolismrisk AT fernandezjosemanuelsoria pharmacologicalcancertreatmentandvenousthromboembolismrisk |